Search
Displaying 341–350 of 470 results for “fut credit Visitez le site Buyfc26coins.com Support incomparable pour mes FC 26 coins.K5QU”
-
Foundation Fighting Blindness Applauds Introduction of LOANS for Biomedical Research Act
Foundation NewsLegislation provides innovative financing for clinical trials stalled by COVID-19 pandemic.
-
The bill would provide loans to therapy developers ready to launch clinical trials for a broad range of conditions including retinal and eye diseases.
-
In the Press
Uses novel, mutation agnostic optogenetics approach to restore vision in underserved forms of blindness. Company backed by leading life science investors including Octagon Capital, Samsara BioCapital and Casdin Capital, along with founding investors Atlas Venture, Mission BioCapital and Foundation Fighting Blindness.
-
Foundation Fighting Blindness and Usher 1F Collaborative to Launch Natural History Study
Foundation NewsThe project will help identify outcome measures for future clinical trials of potential USH1F therapies.
-
Investing in Cures Summit 2021
The 2021 Investing in Cures Summit (ICS) convenes key stakeholders of the Foundation Fighting Blindness and RD Fund to learn from the world’s leading industry, clinical and retinal science innovators poised to take emerging therapies across the finish line.
-
Foundation Invests $5.5 Million in Seven New Translational Research Projects
Research NewsProjects target a variety of conditions including: age-related macular degeneration, Stargardt disease, retinitis pigmentosa, and Usher syndrome type 3A
-
A Eureka Moment for Paul Yang Boosts Advancement of Vision-Saving RP Drug
Research NewsHis latest Foundation grant is helping move the drug toward a clinical trial
-
Erin’s Unwavering Determination, Then and Now
Beacon StoriesDiagnosed with retinitis pigmentosa at a very young age, growing up, Erin never let her progressive vision loss stop her from keeping up with her friends and siblings. Throughout the 1990s, Erin was featured in several Foundation Fighting Blindness campaigns to raise funds for retinal research. Today, 34-year-old Erin is resilient as ever, still hopeful research will one day find her a cure.
-
Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision
In the PressFormer Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of Luxturna™, to lead development of SparingVision’s proprietary asset, SPVN06, and further pipeline development
-
Research News
The company plans to enroll additional patients as young as four years old
.jpg)
